2p15-16.1 microdeletion syndrome

Lore & Background

The syndrome was first identified in two patients in 2007, and by 2013 only 21 individuals had been documented in medical literature. All reported cases involved de novo deletions—neither parent possessed nor transmitted the mutation. One patient was a genetic mosaic, having some cells with the deletion and others without. The deletions varied in size from 570 kilobases to 5.7 megabases, with three patients sharing a consistent proximal breakpoint but varying distal breakpoints.

Reader's Guide

2p15-16.1 microdeletion syndrome represents a rare but clinically recognizable genetic condition. Its significance lies in the consistent pattern of shared features among affected individuals, which allowed clinicians to define it as a distinct syndrome despite its rarity. The shared clinical features include moderate to severe intellectual disability, characteristic facial features (telecanthus, drooping eyelids, downslanting short palpebral fissures, prominent nasal bridge, high palate with long smooth philtrum, everted lower lip), and various other anomalies such as feeding problems in infancy, microcephaly, optic nerve hypoplasia, hydronephrosis, wide-spaced nipples, short stature, cortical dysplasia, camptodactyly, and pigeon toe. The largest deletion encompasses approximately 15 protein-coding genes, including BCL11A, REL, and XPO1, among others. The de novo nature of the deletions and the presence of a mosaic case highlight the genetic complexity. As of 2013, the syndrome remained extremely rare, with only 21 reported patients, underscoring the challenges in diagnosis and research for ultra-rare disorders.

Did You Know?

• Only 21 people had been reported with 2p15-16.1 microdeletion syndrome in the medical literature by 2013.
• All 21 reported cases involved de novo deletions—neither parent possessed nor transmitted the mutation.
• One patient was a genetic mosaic, having some cells with the deletion and others without.
• The deletion sizes ranged from 570 kilobases to 5.7 megabases.

Discovery and the Question of Rarity

This condition entered the medical record in 2007 when two affected individuals were described, marking the first formal recognition of what would become a newly defined genetic syndrome. The disorder stems from a small deletion on the short arm of chromosome 2, specifically in the 2p15-16.1 region. What made the 2007 cases compelling enough to warrant a new classification was the striking overlap in clinical features between the two patients, suggesting a shared underlying mechanism rather than coincidence. By 2013, the total number of individuals identified in the published medical literature stood at just 21, underscoring how extraordinarily uncommon the condition is. That such a small cohort could nonetheless share a recognizable constellation of traits — from facial morphology to neurodevelopmental outcomes — was sufficient for clinicians to formalize 2p15-16.1 microdeletion as its own distinct syndrome. The rarity also means that much of what is known remains descriptive, drawn from a handful of case reports rather than large cohort studies, and the full spectrum of possible presentations may still be emerging as additional patients are identified.

The Recognizable Clinical Portrait

The individuals carrying this deletion share a distinctive set of physical and developmental traits that together form a recognizable clinical portrait. At the core of the syndrome is moderate to severe intellectual disability, which appears consistently across the reported cases. The facial gestalt is particularly striking: affected individuals tend to display telecanthus, drooping eyelids, downslanting eye contours, and short palpebral fissures. The nasal bridge is prominent, the palate sits high, and the upper lip area shows a long, smooth philtrum paired with an everted lower lip. Beyond the face, a range of additional features appear in some patients, including feeding difficulties during infancy, a smaller-than-expected head circumference, underdeveloped optic nerves, and swelling of the kidney's collecting system. Other reported findings include widely spaced nipples, shorter-than-average stature, abnormal cortical development, bent fingers, and inward-turned toes. The consistency of these overlapping features across geographically and genetically diverse patients is what originally convinced researchers that a single underlying chromosomal change was responsible.

A De Novo Event with Variable Reach

A defining genetic characteristic of this syndrome is that every one of the 21 documented cases arose as a de novo mutation. In each instance, neither parent carried the chromosomal deletion, and the change was not inherited from either side of the family. This means the deletion occurred spontaneously in the affected individual, most likely during gamete formation or very early embryonic development. One patient stands out as a genetic mosaic, meaning that only a subset of their cells harbors the deletion while others do not, adding a layer of complexity to the usual picture. Among the three patients whose breakpoints were mapped in detail, a consistent proximal boundary was identified on chromosome 2, but the distal end varied considerably. The resulting deletion sizes ranged from 570 kilobases up to 5.7 megabases, illustrating that the functional impact can differ depending on how much of the 2p15-16.1 region is lost. This variable reach helps explain why some clinical features appear in all patients while others are seen only in a subset.

The Genes Caught in the Deletion

The largest documented deletion in this syndrome spans a genomic stretch that contains roughly fifteen protein-coding genes, six pseudogenes, and several additional candidates that have not yet been fully characterized. Among the identified genes are those involved in heat-shock protein regulation (AHSA2), B-cell lymphoma and leukemia pathways (BCL11A), DNA repair and ubiquitin-mediated processes (FANCL, USP34), peroxisomal membrane biology (PEX13), RNA modification (PUS10, SNORA70B), and protein export from the nucleus (XPO1). Others include a proto-oncogene (REL), a class-switch recombination regulator (SANBR), a poly(A) polymerase (PAPOLG), a serine/threonine kinase (VRK2), and an uncharacterized protein (C2orf74). The breadth of biological processes represented — from RNA processing to cell signaling to peroxisome function — suggests that the syndrome's diverse clinical features likely arise from the combined loss of multiple genes rather than a single critical one. Because the deletion sizes vary among patients, the exact gene dosage responsible for any given trait remains an active area of investigation.